Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases, provided a clinical program update and reported financial results for the first quarter ended March 31, 2020.
May 11, 2020
· 11 min read